First Trust Capital Management
CLDI icon

First Trust Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

First Trust Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-208
Closed -$4.07M – 234
2022
Q4 		$4.07M Hold
208
– – 0.22% 143
2022
Q3 		$3.94M Buy
+208
New +$3.99M 0.19% 165

Other funds holding CLDI

Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Glazer Capital LLC
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Cubist Systematic Strategies
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
Shaolin Capital Management
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Elequin Capital
Elequin Capital New York $3.36B AUM 11.23% 1-Year Est. Return

First Trust Capital Management's CLDI Position: Q1 2023 in Review

First Trust Capital Management sold out of Calidi Biotherapeutics (CLDI) in Q1 2023, closing a stake of 208 shares — an estimated $4.07M sold.

First Trust Capital Management first reported a position in CLDI in Q3 2022 and held it in 2 quarters. The position peaked at $4.07M in Q4 2022. 26 funds tracked by Wall St. Rank hold CLDI as of Q1 2023.

  • First Trust Capital Management reported no remaining Calidi Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • First Trust Capital Management sold 208 Calidi Biotherapeutics shares in Q1 2023, an estimated $4.07M.
  • First Trust Capital Management first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • First Trust Capital Management's Calidi Biotherapeutics position peaked at $4.07M in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q1 2023.

Based on First Trust Capital Management's 13F filing for Q1 2023, filed 12 May 2023.